AU Patent

AU2022203369B2 — Analogs of deutetrabenazine, their preparation and use

Assigned to Auspex Pharmaceuticals Inc · Expires 2024-04-04 · 2y expired

What this patent protects

Disclosed herein are pharmaceutical compositions comprising an admixture of a deutetrabenazine drug substance and a pharmaceutically acceptable carrier. Said compositions comprise 0.5% or less of compound 1 relative to the concentration of deutetrabenazine and 0.15% or less of …

USPTO Abstract

Disclosed herein are pharmaceutical compositions comprising an admixture of a deutetrabenazine drug substance and a pharmaceutically acceptable carrier. Said compositions comprise 0.5% or less of compound 1 relative to the concentration of deutetrabenazine and 0.15% or less of compound 2 relative to the concentration of deutetrabenazine, wherein deutetrabenazine concentration is based on determination via HPLC. Furthermore, said pharmaceutical compositions are stable when stored at room temperature for one to 24 months. D3CO DCO N C pn , N H )N D3 CGO 0 Compound 1 0 Compound 2

Drugs covered by this patent

Patent Metadata

Patent number
AU2022203369B2
Jurisdiction
AU
Classification
—
Expires
2024-04-04
Drug substance claim
No
Drug product claim
No
Assignee
Auspex Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.